Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics Inc (NQ: ALGS )

1.180 +0.040 (+3.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,739
Open 1.120
Bid (Size) 1.120 (1)
Ask (Size) 1.190 (15)
Prev. Close 1.140
Today's Range 1.100 - 1.190
52wk Range 0.8401 - 2.410
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop... 
Via Talk Markets

Performance

YTD
+25.53%
+25.53%
1 Month
-4.07%
-4.07%
3 Month
-21.33%
-21.33%
6 Month
+27.94%
+27.94%
1 Year
-17.48%
-17.48%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: Aligos Therapeutics Q1 Earnings
Via Benzinga
Aligos Therapeutics Earnings Preview
Via Benzinga
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
A Preview Of Aligos Therapeutics's Earnings
Via Benzinga
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Aligos Therapeutics
Via GlobeNewswire
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
Via Benzinga
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
From Aligos Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.